6,054 Shares in Biogen Inc. $BIIB Acquired by Mediolanum International Funds Ltd

Mediolanum International Funds Ltd purchased a new stake in Biogen Inc. (NASDAQ:BIIB) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 6,054 shares of the biotechnology company’s stock, valued at approximately $1,136,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Empowered Funds LLC grew its stake in Biogen by 64.9% during the first quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock worth $965,000 after buying an additional 2,777 shares during the period. Focus Partners Wealth raised its stake in shares of Biogen by 172.2% in the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock valued at $1,392,000 after acquiring an additional 6,436 shares during the period. Sivia Capital Partners LLC acquired a new position in shares of Biogen during the 2nd quarter valued at $216,000. Cerity Partners LLC lifted its holdings in shares of Biogen by 15.3% during the 2nd quarter. Cerity Partners LLC now owns 46,552 shares of the biotechnology company’s stock valued at $5,847,000 after acquiring an additional 6,184 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its position in Biogen by 13.4% during the 2nd quarter. NewEdge Advisors LLC now owns 2,673 shares of the biotechnology company’s stock worth $336,000 after purchasing an additional 316 shares during the period. 87.93% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BIIB has been the topic of several research reports. Zacks Research lowered Biogen from a “hold” rating to a “strong sell” rating in a research report on Monday, June 29th. Oppenheimer increased their target price on Biogen from $275.00 to $300.00 and gave the company an “outperform” rating in a research note on Thursday, May 14th. Piper Sandler reiterated an “overweight” rating on shares of Biogen in a report on Tuesday, July 14th. Wall Street Zen upgraded Biogen from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, JPMorgan Chase & Co. boosted their price target on Biogen from $175.00 to $185.00 and gave the stock a “neutral” rating in a research report on Thursday, April 23rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Biogen currently has an average rating of “Moderate Buy” and an average target price of $220.57.

Biogen Stock Performance

Shares of BIIB stock opened at $203.16 on Wednesday. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. The company’s fifty day moving average price is $199.55 and its two-hundred day moving average price is $189.45. The firm has a market capitalization of $29.99 billion, a P/E ratio of 21.80 and a beta of 0.16. Biogen Inc. has a 12 month low of $123.38 and a 12 month high of $219.72.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same period in the previous year, the company earned $3.02 earnings per share. The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, research analysts anticipate that Biogen Inc. will post 13.45 earnings per share for the current fiscal year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.